Eleven Biotherapeutics Shifts Focus After Trial Failure

Absorbing a 69% stock price crash after the failure of its pivotal trial of EBI-005 in dry-eye disease, Eleven Biotherapeutics explains why it still has faith in other ocular indications and candidates.